drugset / Trial / NCT00150241

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

NCT00150241

Phase 2 Completed 625 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.

Timeline

Start
2000-02
Primary completion
Completion
2002-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 0.3 mg
Subject Varenicline Small molecule 1 mg

Indications

No indication recorded.